TCGA-97-8547-01A-11R-2403-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- COAGULATION+0.440
- MYOGENESIS+0.380
- HEDGEHOG_SIGNALING+0.320
- PANCREAS_BETA_CELLS+0.320
- KRAS_SIGNALING_UP+0.290
- NOTCH_SIGNALING+0.260
- APICAL_JUNCTION+0.250
- KRAS_SIGNALING_DN+0.250
Top 10 suppressed
- MYC_TARGETS_V1-0.660
- E2F_TARGETS-0.590
- G2M_CHECKPOINT-0.570
- MYC_TARGETS_V2-0.510
- OXIDATIVE_PHOSPHORYLATION-0.500
- PI3K_AKT_MTOR_SIGNALING-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.400
- DNA_REPAIR-0.390
- MTORC1_SIGNALING-0.390
- ANDROGEN_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-A9SP-01A-11R-A39I-07 | — | — | 0.924 |
| 2 | TCGA-XF-AAMJ-01A-11R-A42T-07 | — | — | 0.918 |
| 3 | TCGA-49-4512-01A-21R-1858-07 | — | cohortA1 | 0.915 |
| 4 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.903 |
| 5 | TCGA-49-4490-01A-21R-1858-07 | — | cohortA1 | 0.896 |
| 6 | TCGA-LD-A74U-01A-13R-A33J-07 | — | A | 0.896 |
| 7 | MNG298 | — | — | 0.893 |
| 8 | TCGA-CV-5444-01A-02R-1514-07 | — | — | 0.890 |
| 9 | TCGA-55-8096-01A-11R-2241-07 | — | cohortA1 | 0.889 |
| 10 | SRR2665516 | — | — | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.530 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.110 | Inavolisib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.070 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.060 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |